View the characteristics of the SJLIFE cohort relative to the CCSS cohort. The table was last updated October 31, 2022.
Search
Study Population
| Characteristics | Breakdown | SJLIFE Cohort (n=9366) Dx 1962-2012 |
CCSS Cohort (n=25,665) Dx 1970-99 |
|---|---|---|---|
| Sex | Female | 45.3% | 46.5% |
| Male | 54.7% | 53.5% | |
| Race Ethnicity | White not Hispanic | 76.8% | 79.4% |
| Black not Hispanic | 16.9% | 6.2% | |
| American Indian/Alaska Native | 0.1% | <1.0% | |
| Asian Pacific Islander | 0.5% | 0.5% | |
| Hispanic | 4.0% | 7.8% | |
| Other | 1.5% | 3.3% | |
| Unknown | 0.2% | 1.1% | |
| Primary Diagnosis | Leukemia | 32.1% | 30.7% |
| Lymphoma | 15.3% | 20.3% | |
| CNS tumor | 18.0% | 17.5% | |
| Embryonal tumors | 17.3% | 16.5% | |
| Bone and Soft Tissue Sarcoma | 11.9% | 15.0% | |
| Carcinoma | 0.8% | 0.0% | |
| Other | 4.6% | 0.0% |
Geographic distribution of SJLIFE participants
The SJLIFE cohort is geographically diverse with the largest proportion of participants from the mid-South region of the United States.
Recruitment status of SJLIFE
As of April 30, 2020, for survivors where attempts to contact have been initiated, 80.4% (6006/7467) have been successfully enrolled and 87.8% have enrolled or have confirmed their interest in participating. Of all eligible survivors who are alive, 73.5% (6006/8173) have thus far been enrolled and 80.2% have enrolled or confirmed their interest in participating.
Cohort Recruitment Summary
Survivor participants who have completed their baseline clinical assessment are invited to return for subsequent systematic evaluations at a minimum of every 5 years. As of April 30, 2020: 53% (2776/5229) of survivors who had completed a baseline clinical assessment have returned for one or more subsequent follow-up assessments.
Distribution of Pediatric Cancers
SJLIFE includes all pediatric hematological and solid malignancies.
Monthly New Survivor and Control Enrollments
